Jeeva Clinical Trials Inc.’s Post

CAR T-cell therapy presents ground-breaking technology to revolutionise blood #cancertreatment. The successful delivery of these advanced therapeutics requires progressive economic and infrastructure maturity in a country’s healthcare and life sciences ecosystem, built upon strong partnerships between pharmaceutical, R&D, biotech industries, governments, payers, and healthcare providers.   IQVIA’s latest white paper explores the opportunity for #Singapore to develop as a hub-and-spoke model for #CART delivery in the heart of #SEA. It also explores avenues to bridge affordability gaps for the rest of SEA through private-public partnerships and innovative funding mechanisms, aiming to maximize patients’ access to CAR-T in the region. Read to learn more: https://lnkd.in/gkBJk8FK Tom Hardy - Hassan Chaudhry - Ze Qing Kong - Raghav Sharma - Brian Chan Yong Fung

Good report for CAR T cell therapy!!

One stop solution from concept to commercial.

If 2022 brought a steep decline for biopharma funding, 2023 was the year of the rebound with the level of activity exceeding 2019 levels. The Global Trends in R&D 2024 report shared the following points about 2023’s increase in funding activity: ✔️In 2023 alone, follow-on funding represented about 38% of biopharma funding, for which 91% was comprised of companies headquartered in the U.S. ✔️High profile and high value deals indicate robust interest from investors and innovators in the next generation of therapies. ✔️The shifts in deal activity reflect changes in the types of companies being invested in, their therapeutic focus, and where they are located. Explore the forces driving innovation in R&D by downloading the report: https://bit.ly/4a3B6qJ. #RandD #GlobalHealth

New year, new opportunities! Our 2024 M&A life sciences trends report is out! 🌐 Discover five predictions pointing towards another robust year for pharma M&A and a promising upturn for the MedTech market 🚀 #LifeSciences #Healthcare #MergersAndAcquisitions #IndustryInsights

Pleased to share the release of the Deloitte 2024 Global Life Sciences Sector Outlook report. This is a must-read for those in the life sciences industry looking to understand emerging trends and opportunities within the sector; such as how GenAI can be utilised to accelerate drug discovery and reduce R&D costs. Link here: https://deloi.tt/4b7XEaO

For modern #pharma launches, the investment in creating a positive provider and patient experience is critical for both acquisition and retention during the first year. Elyse Muñoz, PhD, Director, U.S. Research & Insights, explains why in this on-demand webinar: https://bit.ly/3WuRCwf

Chronic illnesses have become more and more prevalent in recent years. With them, drug complexity and delivery methods are getting increasingly intricate. #Pharma companies face an exciting mission: to create groundbreaking therapies with unique formulation needs. Peter Droc, Head of Drug Product Services at Lonza, brilliantly summarizes some of our solutions to complex formulation requirements: https://lnkd.in/dKCPqaHu Isn't it fascinating how we can ensure quality and patient safety, while also decreasing time-to-market? #Lonza #DrugProduct

Do you want to know more about how Delphi panels can accelerate patient access to innovative treatments? 🚀💉💊 Please reach out to us at MAP Patient Access Limited if you would like to watch our recent webinar (at normal speed!) where Ben Barron-Millar and Praptee Ghimire discuss the Delphi panel methodology, its value in market access, and practical considerations for implementing it in your evidence-generation strategy. Please feel free to message me directly or request the recording via this link: https://lnkd.in/dePx8zMP #reimbursement #HTA #pharma #medtech